Back on August 17th I pointed out that according to AIM-listed Advanced Oncotherapy’s FY20 Annual Report, all the warrants exercisable at 25p issued back in July 2017 should have expired. Yet the night before, after-hours, the company had announced the exercise of 500,000 of those warrants. Last night the company slipped out an explanation at 6.14pm in its Result of GM announcement.
Here is an odd thing: last night, after hours at 4.48pm, AIM-listed Advanced Oncotherapy (AVO) announced that someone had issued an exercise notice in respect of 500,000 warrants issued back in July 2017 to subscribe for ordinary shares at 25p. Application to admit the shares has been made and admission is expected on or around August 20th. So what, you might ask. And that brings me to Advanced’s Annual Report for FY20.
AIM-listed protons beams for cancer outfit Advanced Oncotherapy (AVO) announced a proposed £40 million fundraise yesterday – the largest to date – at 40p per share, a 17% premium to its average closing price over the past month, and a 13% premium to the previous close. I have to hand it to the company, that’s a great effort. But does it make the shares a buy?
When I last wrote about AIM-listed Advanced Oncotherapy, at the end of October last year, it had just announced a placing at 30p per share to raise £7.7 million and my back-of-a-fag-packet suggested that despite the new money, it was placing ahoy. Well, yesterday that placing duly arrived with £6 million raised at a rather more impressive 40p. So will this be the last time the company passes round the hat?
AIM-listed Advanced Oncotherapy (AVO) has announced a fundraise at 30p to raise £7.7 million (before expenses) – as predicted HERE by yours truly. Time for another glass of Ouzo, methinks.
Yesterday AIM-listed Advanced Oncotherapy (AVO) announced a new joint broker in the form of SI Capital. Today we have a ramptastic update…..should we draw a conclusion?
